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Human Papillomavirus E7 Oncoprotein Transgenic
Skin Develops an Enhanced Inflammatory Response to
2,4-Dinitrochlorobenzene by an Arginase-1-Dependent
Mechanism
Le Son Tran1, Anne-Sophie Bergot1, Stephen R. Mattarollo1, Deepak Mittal1,2,3 and Ian H. Frazer1,2
We have shown that the expression of human papillomavirus type 16 E7 (HPV16.E7) protein within epithelial cells
results in local immune suppression and a weak and ineffective immune response to E7 similar to that occuring in
HPV-associated premalignancy and cancers. However, a robust acute inflammatory stimulus can overcome this to
enable immune elimination of HPV16.E7-transformed epithelial cells. 2,4-Dinitrochlorobenzene (DNCB) can elicit
acute inflammation and it has been shown to initiate the regression of HPV-associated genital warts. Although the
clinical use of DNCB is discouraged owing to its mutagenic potential, understanding how DNCB-induced acute
inflammation alters local HPV16.E7-mediated immune suppression might lead to better treatments. Here, we
show that topical DNCB application to skin expressing HPV16.E7 as a transgene induces a hyperinflammatory
response, which is not seen in nontransgenic control animals. The E7-associated inflammatory response is
characterized by enhanced expression of Th2 cytokines and increased infiltration of CD11bþGr1intF4/80þ
Ly6ChiLy6Glow myeloid cells, producing arginase-1. Inhibition of arginase with an arginase-specific inhibitor,
N(omega)-hydroxy-nor-L-arginine, ameliorates the DNCB-induced inflammatory response. Our results demon-
strate that HPV16.E7 protein enhances DNCB-associated production of arginase-1 by myeloid cells and
consequent inflammatory cellular infiltration of skin.
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INTRODUCTION
Persistent infection with oncogenic human papillomaviruses
(HPV), particularly HPV16, is associated with selective
expression of two virally encoded proteins (E6 and E7). One
action of HPV16.E7 protein is to subvert the innate immune
system (Frazer et al., 1998) through the downregulation
of IFNg pathways, modulation of antigen presentation,
and suppression of Toll-like receptor 9 protein (Bhat et al.,
2011).
K14.E7 transgenic mice, which express HPV16.E7 onco-
protein within basal keratinocytes under the control of the
keratin 14 transcriptional promoter, have been extensively
used as a model of HPV oncoprotein–induced immune
suppression associated with human squamous cancers, in
which only the E6 and E7 genes of the papillomavirus are
expressed (Trimble and Frazer, 2009). We have previously
shown that skin grafts expressing HPV16.E7 oncoprotein are
not spontaneously rejected when transplanted onto syngeneic
animals, but they are rejected when certain components of the
innate immune system are unavailable, confirming that the
expression of HPV16.E7 in the epithelium results in the
establishment of a local suppressive environment and the
subversion of antigen-specific T cells (Mattarollo et al., 2010;
Mittal et al., 2013). Therefore, successful strategies targeting
HPV-associated cancer need to circumvent or disrupt the local
suppressive environment.
Topical immunotherapy with immunostimulatory agents
has been used clinically to treat cancerous lesions including
squamous cell and basal cell carcinoma in immunocompetent
and immunosuppressed patients (Hengge et al., 2001). Topical
application of 2,4-dinitrochlorobenzene (DNCB) is an
effective therapy for condylomata acuminata caused by HPV
infection. DNCB induced the complete clearance of HPV-
associated warts in 13/15 patients (Georgala et al., 1989).
The efficacy of this treatment is attributed to the immuno-
stimulatory role of DNCB that might activate cell-mediated
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immunity (Belij et al., 2012). However, the use of DNCB for
treatment has been discouraged because of its mutagenic
potential (Black et al., 1985). We speculated that under-
standing how induction of a vigorous acute inflammatory
response by DNCB can break the locally immune-suppressive
environment and restore the effector function of adaptive
immunity might lead to more acceptable treatments for
persisting HPV infection.
Arginase, which metabolizes L-arginine to N-ornithine and
urea, has been identified as a crucial regulator of inflamma-
tion. Mammalian cells express two different isoforms, argi-
nase-1 and arginase-2, which are encoded by two distinct
genes and are different in their tissue distribution and
subcellular localization (Bronte and Zanovello, 2005).
Arginase can function as an immunosuppressive factor in the
tumor environment (Ochoa et al., 2007), in virus (Tacke et al.,
2012), or in parasite infection (Mou et al., 2013). However,
this enzyme has also been identified as an important
proinflammatory factor in numerous disease models (Kenyon
et al., 2008; Zhang et al., 2009; Stoermer et al., 2012). As
inflammation decides the fate of HPV infection and arginase
is an important regulator of inflammation and immunity,
we investigated the interaction between DNCB-induced
inflammation and HPV16.E7 protein in induction of arginase
in K14.E7 transgenic mice. We show here that K14.E7
transgenic mice exhibit an enhanced local inflammatory
response to DNCB treatment, compared with nontrans-
genic mice, and that myeloid cells express increased
arginase-1, which specifically promotes DNCB-induced
inflammation.
RESULTS
K14.E7 mice develop a robust inflammation response to DNCB
An inflammatory response was induced in wild-type non-
transgenic C57BL/6 and in E7 transgenic K14.E7 mice by
applying DNCB topically to the ear skin. The mean increase in
ear thickness was monitored as an indicator of inflammatory
reaction (Pinto et al., 2010). K14.E7 mice displayed a signi-
ficantly higher degree of ear swelling than C57BL/6 mice,
which peaked at day 3 in response to a single application of
DNCB (Figure 1a).
T lymphocytes have been found in several skin inflamma-
tion diseases and have an important role in the production
of inflammatory cytokines and in the recruitment of innate
immune cells (Bromley et al., 2013). They also drive the
enhanced inflammatory response seen on repeated exposure
to DNCB (Wang et al., 2000). In addition, our previous study
showed that lymphocytes are increased in number in K14.E7
skin (Choyce et al., 2013). Therefore, we investigated whether
the enhanced inflammatory response to first exposure to
DNCB in K14.E7 skin was dependent on local lymphocyte
function. K14.E7 mice deficient in lymphocytes (Rag /  E7),
when exposed to DNCB, exhibited a similar level of ear
swelling as K14.E7 mice, and stronger than control Rag /
mice over 5 days after DNCB treatment (Figure 1a). Thus,
DNCB-treated K14.E7 mice exhibit a hyperinflammatory
response on first exposure to DNCB, which is independent
of an adaptive immune response.
DNCB-treated K14.E7 skin displays an enhanced infiltration of
myeloid cells and Th2 cytokine expression
To characterize further the inflammation in DNCB-treated
K14.E7 skin, we examined the infiltration of immune cells.
Histological examination suggested that the greater ear swel-
ling in K14.E7 mice corresponded to a significant increase in
the number of immune cells infiltrating the dermis (Figure 1b).
As expected, the thickness of the K14.E7 epidermal layer
remained unchanged following DNCB treatment (control:
42.4±3.7mm, DNCB: 40±3.5mm). Rag /  E7 mice
develop similar ear swelling and inflammatory cell infiltration
in the dermis as K14.E7 mice, whereas control Rag / mice
do not (Figure 1a and b). Thus, the increased ear swelling in
K14.E7 in response to DNCB mice was mainly contributed by
infiltration of cells of the innate immune system in the dermis,
and it was independent of lymphocytes.
Flow cytometry analysis revealed that DNCB-treated
K14.E7 ears recruited significantly higher numbers of myeloid
cells (CD45.2þCD11bþ ) than similarly treated C57BL/6
ears. We observed the same trend when we compared
Rag /  E7 mice with Rag / mice (Figure 2a). In contrast,
the number of non-myeloid bone marrow–derived cells
(CD45.2þCD11b ) remained unchanged and was compar-
able in all four groups following DNCB treatment (Figure 2b).
Thus, the expression of HPV16.E7 in the skin mediates the
enhanced recruitment of myeloid cells, and this effect is
independent of adaptive immunity.
IL-1b and IL-6 are major cytokines secreted from the local
inflammation site and promote the recruitment of innate
immune cells (Zohlnhofer et al., 2000; Fielding et al., 2008).
DNCB treatment resulted in a significant increase in IL-1b
messenger RNA (mRNA) expression in both C57BL/6 and
K14.E7 skin (Table 1). In addition, IL-6 mRNA expression
was significantly increased in DNCB-treated K14.E7 skin but
not in nontransgenic skin, suggesting that IL-6 might be
responsible for the enhanced recruitment of myeloid cells in
K14.E7 skin.
Further, DNCB treatment of K14.E7 mice significantly
induced mRNA expression of prostaglandin E2 synthase and
Th2 cytokines IL-4 and IL-10. In contrast, there was no signi-
ficant change in the expression of these factors in DNCB-
treated C57BL/6 mice. Th1 cytokines displayed decreased
(tumor necrosis factor-a) or unaltered (interferon gamma)
expression after DNCB treatment (Table 1).
Together, these results suggest that after a single DNCB
treatment to previously unexposed animals, K14.E7 mice
mounted an enhanced inflammatory response, which is
accompanied by CD45.2þCD11bþ myeloid cell infiltration
and amplified Th2 cytokine expression.
Arginase-1 is specifically induced in DNCB-treated K14.E7 mice
Inflammation and myeloid cell activation can be associated
with the induction of arginase (Bronte et al., 2003). We
speculated that arginase activity might contribute to enhanced
inflammation of K14.E7 skin in response to DNCB. To test this
hypothesis, we first investigated arginase activity in the skin
of C57BL/6 and K14.E7 mice following DNCB treatment.
Arginase activity was comparable in control K14E7 and
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C57BL/6 ear skin (Figure 3a), as was arginase mRNA expres-
sion (Figure 3b and RNAseq data not shown). DNCB-treated
K14.E7 skin, however, demonstrated a substantially higher
amount of arginase activity than DNCB-treated C57BL/6 skin
(Figure 3a). Arginase activity is contributed by two arginase
isoforms. Increased arginase activity in K14.E7 mice corre-
sponded to markedly increased (fourfold) arginase-1 mRNA
expression. Conversely, the expression of arginase-1 mRNA
remained unchanged in DNCB-treated C57BL/6 mice
(Figure 3b). In contrast to arginase-1, there was no significant
induction of arginase-2 mRNA in either C57BL/6 or K14.E7
skin (Figure 3c).
K14.E7 mice lacking lymphocytes (Rag /  E7) not only
exhibited a similar level of ear swelling as K14.E7 mice but
also of arginase-1 mRNA and arginase activity following
DNCB treatment. Notably, Arginase-1 and arginase-2 mRNA
expression are not increased in control Rag / mice follow-
ing DNCB treatment (Figure 3b and c). Thus, the induction
of arginase in K14.E7 skin is independent of adaptive
immunity.
To examine whether the induction of arginase was unique
to skin expressing HPV16.E7 oncoprotein as a transgene,
K14.hGh and K5.OVA mice expressing human growth hor-
mone or ovalbumin, respectively, under the control of keratin
promoters were treated with DNCB. In contrast to K14.E7
mice, there was no change in the level of arginase activity
of K14.hGh or K5.OVA mice following DNCB treatment
(Figure 3d). Furthermore, the ear swelling of these transgenic
mice (K5.OVA: 2.25±0.5mm; K14.hGh: 1.75±0.5mm, day 5)
was similar to that of C57BL/6 mice (1.75±0.5mm, day 5) and
markedly lower than in K14.E7 mice (19.8±9.9mm, day 5).
Thus, these results suggest that increased arginase activity,
likely derived from activated myeloid cells, might be a
consequence of exposure of K14.E7-expressing epithelial cells
to DNCB.
CD11bþGr1intF4/80þLy6ChiLy6Glow cells are the major source
of arginase-1 in DNCB-treated K14.E7 mice
Arginase-1 can be induced in myeloid cells including macro-
phages, dendritic cells, and myeloid-derived suppressive cells
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Figure 1. K14.E7 mice exhibit an enhanced inflammatory response to 2,4-dinitrochlorobenzene (DNCB). Ear swelling of C57BL/6, K14.E7, Rag / , and
Rag /  E7 mice in response to DNCB or vehicle over 5 consecutive days (a) measured by caliper. Data are means±SEM, and are representative of two
independent experiments with four mice per group. ***Po0.001. Histology of representative sections from C57BL/6, K14.E7, Rag /  E7, and Rag /mice
(b) at 1 day post DNCB or vehicle application. Hematoxylin and eosin stain, original magnification 200, scale bar¼ 100mm (representative of four
mice per group).
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in response to a wide range of stimuli (Sindrilaru et al., 2011;
Chang et al., 2013). These myeloid cells express surface
CD11b (Hammad and Lambrecht, 2008). To confirm whether
myeloid cells were the source of DNCB-induced arginase-1 in
K14.E7 skin, CD45.2þCD11b and CD45.2þCD11bþ cells
(Supplementary Figure S1 online) were isolated from DNCB-
treated C57BL/6 and K14.E7 mice and analyzed for arginase
activity and arginase-1 mRNA expression. CD11bþ myeloid
cells from DNCB-treated K14.E7 mice produced significantly
higher levels of arginase activity per cell compared with
CD11b cells, and compared with CD11bþ myeloid cells
from DNCB-treated C57BL/6 mice (Figure 4a). In addition,
arginase-1 mRNA expression was substantially detected in
CD45.2þCD11bþ cells in DNCB-treated K14.E7 mice,
but not in CD11b or CD11bþ cells from C57BL/6 mice
(Figure 4b). Although arginase-2 mRNA was also detected in
CD45.2þCD11bþ cells in K14.E7 skin, arginase-2 mRNA
expression was 10 times lower than arginase-1 (Figure 4b).
Thus, DNCB-activated myeloid cells (CD45.2þCD11bþ )
produce the increased arginase-1 observed in DNCB-treated
K14.E7 skin.
CD11b is expressed on different myeloid subsets including
macrophages/monocytes and granulocytes. To further define
which cell subset expresses arginase-1 in DNCB-treated
K14.E7 mice, we examined the expression level of arginase-
1 in different populations of CD11bþ cells based on the
expression of macrophage marker F4/80 and granulocyte
marker Gr1. We found that F4/80þGr1int cells expressed
significantly higher levels of arginase-1 than other cell popula-
tions (Figure 4c). Furthermore, arginase-1 was abundantly
expressed in inflammatory monocytes that express Ly6ChiLy6-
Glow but not in Ly6ClowLy6Ghi granulocytes (Figure 4d).
Suppression of arginase ameliorates the ear swelling of inflamed
K14.E7 skins
Arginase can be paradoxically involved in the upregulation
or downregulation of inflammatory responses. N(omega)-
hydroxy-nor-L-arginine (nor-NOHA), which is an intermediate
in the L-arginine/NO pathway, is widely used as a specific,
reversible inhibitor of arginase both in vitro and in vivo
(Tenu et al., 1999; Bratt et al., 2009). To understand whether
arginase promoted or suppressed the inflammatory response of
K14.E7 mice to DNCB, we administered nor-NOHA or saline
buffer to K14.E7 mice 1 day before DNCB treatment and daily
for 4 days.
Ear tissue was harvested after 24 hours of DNCB treatment
with or without arginase inhibitor, and the expression and
activity of arginase were determined. Nor-NOHA, as expected,
did not suppress the transcription of arginase-1 gene
(Figure 5a), but reduced arginase activity in DNCB-treated
K14.E7 skin (Figure 5b).
Furthermore, swelling of DNCB-treated K14.E7 skin was
reduced in animals treated with arginase inhibitor (Figure 5c).
Consistent with the ear swelling data, arginase inhibition
decreased the number of infiltrating cells in the dermis of
DNCB-treated K14.E7 mice (Figure 5d and e). These
results demonstrate that arginase-1 induced by DNCB in
K14.E7 transgenic ear skin, but not in C57BL/6 ear skin,
itself contributes to exacerbated inflammatory response to
DNCB in K14.E7 skin by recruitment of further inflammatory
cells.
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Figure 2. K14.E7 mouse skin has an enhanced myeloid cell infiltration in
response to 2,4-dinitrochlorobenzene (DNCB). Absolute counts of leukocyte
cells in the skin of C57BL/6 (n¼4), K14.E7 (n¼ 6), Rag / (n¼5), and
Rag /  E7 (n¼5) mice following DNCB treatment. Absolute numbers of
CD45.2þCD11bþ myeloid cells (a) and CD45.2þCD11b cells (b) were
determined by flow cytometry. Data are presented as means±SEM and are
representative of two independent experiments. NS, not significant. **Po0.01,
***Po0.001.
Table 1. Expression of cytokine mRNA in response to
DNCB or vehicle in K14E7 and C57 mice
Expression relative to housekeeping gene
RPL32
C57BL/6 K14.E7
Cytokine Vehicle DNCB Vehicle DNCB P
IL-1b ( 104) 6.8±0.8 51±4 221±132 1490±900 #, þ , *, @
IL-6 (104) 50±8 55±29 142±103 5310±2870 þ , @
IL-4 (1011) 1.3±2.2 3.0±3.1 15.1±14.2 74.5±53.3 þ , @, *
Ptge2s (104) 75±74 91±127 158±34 480±124 þ , @
IL-10 ( 104) 0.4±0.3 0.8±0.8 4.0±1.1 7.0±1.6 þ , *
IFNg (104) 0.2±0.2 0.11±0.12 1.9±1.1 1.1±0.9 *
TNFa ( 104) 3.2±2.9 2.7±1.6 41.3±15.2 3.4±2.2 *, @
Abbreviations: DNCB, dinitrochlorobenzene; mRNA, messenger RNA;
Ptge2s, prostaglandin E2 synthase; TNFa, tumor necrosis factor-a.
#Po0.05 C57 DNCB versus vehicle.
þPo0.05 K14E7 DNCB versus vehicle.
*Po0.05 K14E7 vehicle versus C57 vehicle.
@Po0.05 change in expression for DNCB-treated K14E7 versus DNCB-
treated C57.
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Figure 3. Arginase-1, but not arginase-2, is induced in K14.E7 mice following 2,4-dinitrochlorobenzene (DNCB) treatment, and this regulation is
lymphocyte independent. Arginase activity was measured by determining the release of urea product from 100mg of protein lysate per sample. Protein lysates were
prepared from ear tissues of DNCB or vehicle-treated C57BL/6, K14.E7, Rag / , Rag /  E7, K14.HgH, and K5.OVA ear tissues. Relative gene expression
levels of (b) arginase-1 and (c) arginase-2 messenger RNAs were determined by real-time PCR in the skin of C57BL/6, K14.E7, Rag / , and Rag /  E7 mice
1 day following DNCB treatment, normalized against the housekeeping gene RPL32. Data are presented as means±SEM and are representative of two
independent experiments (n¼ 4 mice per group). NS, not significant. *Po0.05.
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Figure 4. CD11bþ Gr1int F4/80þ Ly6GlowLy6Chi cells produce arginase in 2,4-dinitrochlorobenzene (DNCB)-treated K14.E7 skin. Arginase activity
produced by CD45.2þCD11bþ and CD45.2þCD11b populations from DNCB-treated C57BL/6 and K14.E7 mice (a) was determined as described in Materials
and Methods. Arginase-1 and arginase-2 mRNA expression (b) levels were determined by real-time PCR. Arginase-1 messenger RNA (mRNA) expression levels in
Gr1F4/80þ ; Gr1intF4/80þ ; Gr1hiF4/80þ ; and Gr1F4/80 subsets from DNCB-treated K14.E7 mice were determined (c) by real-time PCR. Real-time PCR
analysis of arginase-1 mRNA expression in different cell subsets (d) was based on the expression of Ly6C and Ly6G antigens. Data were pooled from four
independent experiments. In each experiment, six C57BL/6 and two K14.E7 mice were treated with DNCB or vehicle. Means±SEM. NS, not significant. *Po0.05.
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DISCUSSION
DNCB triggers a T-cell–independent inflammatory response
through the activation of the NALP-3 inflammasome in
keratinocytes (Schuepbach-Mallepell et al., 2013), and it has
been used to treat HPV-associated genital warts. Despite its
efficacy, this chemical is potentially mutagenic and carcino-
genic (Black et al., 1985). Therefore, we sought to understand
the influence of the expression of the major oncogenic protein
of HPV16, E7, on the inflammatory mechanism induced by
DNCB using mice transgenic for the E7 protein expressed in
keratinocytes. Here, we show that the acute response to
DNCB in previously unexposed mice is significantly higher
in K14.E7 transgenic mice than in nontransgenic mice.
In response to DNCB-induced inflammasome activation,
keratinocytes have been shown to produce a wide range of
proinflammatory cytokines including IL-6 and IL-1b (Enk and
Katz, 1992; Rambukkana et al., 1996), which are known to
be responsible for the recruitment of polymorphonuclear cells
(Zohlnhofer et al., 2000; Fielding et al., 2008). We indeed
found an increased number of inflammatory myeloid cells in
the dermis and enhanced mRNA expression levels of IL-6 and
IL-1b, in DNCB-treated K14E7 transgenic mice, and show
further that DNCB-induced IL-1b and IL-6 production was
greatly enhanced in K14E7 skin when compared with non-
transgenic skin. We could not detect significant induction of
IL-6 in nontransgenic skin. Therefore, we hypothesize that this
cytokine might be a regulator of inflammatory cell infiltration
in K14.E7 skin and its ear swelling. Premalignant skin of
HPV16.E7 transgenic mice is characterized by hyperplastic
epidermis and infiltration of innate immune cells of myeloid
origin. The presence of these cells in K14.E7 skin might
be responsible for the marked inflammatory response to
short-term DNCB treatment and inflammasome activation.
Interestingly, we were not able to detect these responses to
DNCB in other transgenic skin including K14.hGh and
K5.OVA, suggesting that they are unique to K14.E7 mice,
a consequence of the presence of HPV.E7 oncoprotein in
the skin.
DNCB treatment of K14.E7 mice significantly induced
mRNA expression of Th2 cytokines IL-4 and IL-10, when
compared with wild-type mice. This finding is consistent with
the finding in a mouse model of allergic skin inflammation, in
which Th2 cytokines are responsible for the amplification
and chronicity of allergic skin inflammation (Masuoka et al.,
2012), and with a study in which IL-4-deficient mice displayed
an impaired ear swelling response to DNCB application
(Traidl et al., 1999). Furthermore, we show that DNCB-
treated K14.E7 skin exhibited an accumulation of CD11bþ
myeloid cells, but not of non-myeloid bone marrow–derived
cells, which are mainly lymphocytes. Th2 cytokines induce
arginase activity in myeloid cells including macrophages and
dendritic cells (Munder et al., 1999; Barron et al., 2013).
Arginase-2 can be expressed by macrophages, and it has
structural and enzyme characteristics similar to arginase-1
(Khallou-Laschet et al., 2010), but it remained unchanged
in K14.E7 skin. Thus, the higher level of arginase activity
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Figure 5. Inhibition of arginase ameliorates the ear swelling of dinitrochlorobenzene (DNCB)-treated K14.E7 mice. Mice were injected with 500mg of arginase
inhibitor (No-hydroxy-nor-L-arginine (nor-NOHA)) or saline buffer 1 day before DNCB treatment and daily for 5 days. Arginase-1 messenger RNA (mRNA)
expression (a) and arginase activity (b) in saline or nor-NOHA-treated K14.E7 mice after 24 hours of exposure to DNCB, determined by real-time PCR and
arginase assay, respectively. Ear swelling of K14.E7 mice treated with saline (solid line) or nor-NOHA (dashed line) monitored during 5 days after DNCB
treatment (c). Histological sections (d) and quantification of cell numbers infiltrating into the dermis from Nor-NOHA or saline-treated K14.E7 skins 1 day following
DNCB application (e). Means±SEM, data show results from two independent experiments (n¼ 5). NS, not significant; PBS, phosphate-buffered saline.
*Po0.05, **Po0.01, ***Po0.001, ****Po0.0001.
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in DNCB-treated K14.E7 mice is mainly contributed by
arginase-1, and is promoted possibly by higher levels of Th2
cytokines and by accumulation of myeloid cells.
One predicted source of enhanced Th2 cytokine production
in DNCB-treated K14E7 skin would be Th2 CD4þ lympho-
cytes. Indeed, K14E7 skin has a large number of CD4þ
lymphocytes (Choyce et al., 2013). However, we demon-
strate here that the induction of arginase-1 and enhanced ear
swelling response of K14.E7 skin are independent of lympho-
cytes. Th2 cytokines, which induce arginase-1 expression and
hyperinflammatory response in DNCB-treated K14.E7, might
therefore be derived from innate immune cells (Bradding
et al., 1992; Kuroda et al., 2009) or epithelial cells (Balato
et al., 2012). We also detected the induction of prostaglandin
E2 synthase in DNCB-treated K14.E7 skin. Our data are
consistent with a previous study that HPV16.E7 oncoprotein
induced cyclooxygenase 2 transcription and prostaglandin E2
synthase production (Subbaramaiah and Dannenberg, 2007).
Furthermore, the cyclooxygenase 2–Pteg2s synthase axis has
been shown to induce arginase-1 in myeloid cells in a tumor
environment (Rodriguez et al., 2005). However, further studies
are needed to address the induction mechanism of arginase-1
in DNCB-treated K14.E7 skin.
Cells producing arginase-1 in K14.E7 skin were positive for
F4/80 and Ly6C antigen, and express Gr1 at the intermediate
level. This population has been defined as monocytic myeloid
suppressive cells or inflammatory monocytes, which appear to
adopt an immune stimulatory or suppressive function depend-
ing on the local environment (Kallberg et al., 2012). Indeed,
CD11bþGr1þ cells during the early phase of polymicrobial
sepsis exhibit proinflammatory phenotypes, whereas this cell
population becomes immature and immune suppressive in the
late phase (Brudecki et al., 2012).
To understand the role of arginase in the hyperinflammation
in K14.E7 skin, we used the compound nor-NOHA, which
efficiently suppresses arginase-1 and arginase-2 activity in
in vitro and in vivo studies (Tenu et al., 1999; Bratt et al.,
2009). Nor-NOHA abrogates the function of arginase by
modifying the structure of the enzyme, and it does not affect
the transcription of the arginase gene, consistent with
an unaltered arginase mRNA level (Krotova et al., 2010).
Arginase inhibitor treatment decreased the arginase activity
and the level of leukocyte infiltrate and ear swelling in DNCB-
treated K14.E7 mice. This suggests that enhanced arginase
activity is critically required for the strong and sustained
inflammatory response and that arginase inhibitor alleviates
DNCB-induced inflammation by decreasing the recruitment of
leukocytes in the skin. Arginase efficiently competes with
inducible nitric oxide synthase for the common substrate L-
arginine, leading to the inhibition of inducible nitric oxide
synthase expression and NO production. As endothelium-
derived NO is reported to suppress the expression of adhesion
molecules such as vascular cell adhesion molecule-1 and
intercellular adhesion molecule-1 (Peng et al., 1998), limiting
of NO bioavailability through arginase results in enhanced
vascular inflammation (White et al., 2006). In a mouse model
of atherogenesis, arginase-2 but not arginase-1 enhances
monocyte adhesion to endothelial cells and triggers the
production of proinflammatory cytokines through mitochon-
drial reactive oxygen species (Ming et al., 2012). Liu et al.
(2013) show that infiltrating myeloid cells produce arginase-1,
which promotes angiogenesis and further recruitment of
monocytes in a laser-induced injury murine model.
Taken together, our findings demonstrate that HPV16.E7
oncoprotein–expressing skin develops a hyperinflammatory
response to DNCB via an arginase-1-dependent mechanism.
These findings provide insights into the proinflammatory role
of arginase-1 in HPV16.E7-expressing skin in response to
immunostimulation by DNCB.
MATERIALS AND METHODS
Mice
K14.HPV16E7 (K14.E7) mice were generated from inbred strain
C57BL/6 (Narayan et al., 2009). K14.E7, K14.HgH, and Rag / ,
all on a C57BL/6 background, were purchased from Animal
Resources Center (Perth, Australia). K5.mOVA mice on a C57BL/6
background were kindly provided by H. Azukizawa (Azukizawa
et al., 2003). Rag /  E7 mice were generated by crossing male
K14.E7 with female Rag1 / knockout C57BL/6 mice; heterozygous
K14E7 mice were crossed and then backcrossed with homozygous
Rag1 / mice to an F2 generation (Narayan et al., 2009). All mice
were maintained under specific pathogen-free conditions at Princess
Alexandra Hospital Biological Research Facility. Experimental mice
were sex-matched and used at 6–9 weeks of age. All animal
procedures complied with guidelines approved by the University of
Queensland Animal Ethics Committee.
DNCB treatment
DNCB (Sigma, Sydney, New South Wales, Australia) was dissolved in
vehicle (acetone: olive oil (4:1)) immediately before use. Six- to nine-
week-old mice were treated with 20ml of 1% DNCB or vehicle on the
left ear and right ear, respectively. After 24 hours, the ear tissues were
collected for mRNA and protein analysis. Ear thickness was measured
by using the digital caliper, and change in ear swelling was
determined by calculating the mean increase in ear thickness
compared with untreated ears.
Histological analysis
Ear tissues were fixed using 4% paraformaldehyde. Tissues were
embedded in paraffin and 7-mm sections were prepared and stained
with hematoxylin and eosin. Immune cell infiltration was evaluated
by light microscopy and quantified by using the Nis-elements Br 3.2
software (Nikon Instruments, New York, NY).
Real-time PCR
RNA was isolated from homogenized tissues by using the RNaeasy
Mini kit (Qiagen, Melbourne, Victoria, Australia). RNA extracts were
quantified using absorption of light at 260 and 280 nm (A260/280).
Details of the procedures and primers used for the quantitative real-
time PCR are described in Supplementary Methods online.
Arginase activity
Arginase activity was measured by colorimetric determination of urea
formed from L-arginine, as previously described (Chang et al., 2000).
Details of the procedures are desbribed in Supplementary Methods
online.
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Flow cytometry and cell sorting
Flow cytometry staining was performed as previously described
(Mattarollo et al., 2010). Details of flow cytometry and cell sorting
are described in Supplementary Methods online.
Statistical analysis
Each data point represents the mean±SEM and is representative of
two independent experiments with at least four mice per group. Prism
(Graph pad Software, La Jolla, CA) was used for graphs and statistical
analysis: *Po0.05; **Po0.01; ***Poo0.001; ****Po0.0001. Multi-
ple comparisons of ear swelling data were derived by two-way
analysis of variance. For other data, statistically significantly
differences between groups were analyzed by nonparametric t-test
(Mann–Whitney test).
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